EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Probiotic-Based Oral Vaccine against SARS-CoV-2 Omicron Variant B.1.1.529

Eddie Chung Ting Chau, Tsz Ching Kwong iD, Chun Keung Pang, Lee Tung Chan, Andrew Man Lok Chan, Xiaoqiang Yao iD, John Siu Lun Tam, Shun Wan Chan, George Pak Heng Leung iD, William Chi Shing Tai iD, Yiu Wa Kwan

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241813931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Eddie Chung Ting Chau und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Health Bureau of the Government of the Hong Kong Special Administrative Region of the People's Republic of China, Health and Medical Research Fund from the Research Council under the Health Bureau of the Government of the Hong Kong Special Administrative Region of the Peop….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID-19 pandemic, caused by the SARS-CoV-2 virus, is still affecting the entire world via the rapid emergence of new contagious variants. Vaccination remains the most effective prevention strategy for viral infection, yet not all countries have sufficient access to vaccines due to limitations in manufacturing and transportation. Thus, there is an urgent need to develop an easy-to-use, safe, and low-cost vaccination approach. Genetically modified microorganisms, especially probiotics, are now commonly recognized as attractive vehicles for delivering bioactive molecules via oral and mucosal routes. In this study, Lactobacillus casei has been selected as the oral vaccine candidate based on its’ natural immunoadjuvant properties and the ability to resist acidic gastric environment, to express antigens of SARS-CoV-2 Omicron variant B.1.1.529 with B-cell and T-cell epitopes. This newly developed vaccine, OMGVac, was shown to elicit a robust IgG systemic immune response against the spike protein of Omicron variant B.1.1.529 in Golden Syrian hamsters. No adverse effects were found throughout this study, and the overall safety was evaluated in terms of physiological and histopathological examinations of different organs harvested. In addition, this study illustrated the use of the recombinant probiotic as a live delivery vector in the initiation of systemic immunity, which shed light on the future development of next-generation vaccines to combat emerging infectious diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VaccinesAnimalsCricetinaeHumansSARS-CoV-2COVID-19 VaccinesPandemicsMesocricetus

Stichwörter der Autor:innen

COVID-19Lactobacillus caseiOmicroninfectious diseaseoral vaccine

Substanzen

COVID-19 VaccinesVaccines

Autor:innen und Institutionen

  • School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.
  • Department of Food and Health Sciences, Faculty of Science and Technology, Technological and Higher Education Institute of Hong Kong, Hong Kong, China.
  • Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China.

ORCID-Profile: Tsz Ching Kwong, Xiaoqiang Yao, George Pak Heng Leung, William Chi Shing Tai

Förderung

  • The Health Bureau of the Government of the Hong Kong Special Administrative Region of the People's Republic of China
  • Health and Medical Research Fund from the Research Council under the Health Bureau of the Government of the Hong Kong Special Administrative Region of the Peop…

Zitieren

APA

Chau, E. C. T., Kwong, T. C., Pang, C. K., Chan, L. T., Chan, A. M. L., Yao, X., Tam, J. S. L., Chan, S. W., Leung, G. P. H., Tai, W. C. S., & Kwan, Y. W. (2023). A Novel Probiotic-Based Oral Vaccine against SARS-CoV-2 Omicron Variant B.1.1.529. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241813931

Vancouver

Chau ECT, Kwong TC, Pang CK, Chan LT, Chan AML, Yao X, et al. A Novel Probiotic-Based Oral Vaccine against SARS-CoV-2 Omicron Variant B.1.1.529. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241813931

BibTeX
@article{Chau2023,
  author = {Chau, Eddie Chung Ting and Kwong, Tsz Ching and Pang, Chun Keung and Chan, Lee Tung and Chan, Andrew Man Lok and Yao, Xiaoqiang and Tam, John Siu Lun and Chan, Shun Wan and Leung, George Pak Heng and Tai, William Chi Shing and Kwan, Yiu Wa},
  title = {A Novel Probiotic-Based Oral Vaccine against SARS-CoV-2 Omicron Variant B.1.1.529},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241813931}
}
Kostenlos starten →